These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38691509)

  • 21. Naloxone availability in independent community pharmacies in Georgia, 2019.
    Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of naloxone furnishing community pharmacies in San Francisco.
    Nguyen AM; Kearney TE; Apollonio DE
    J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.
    Marotta PL; Abbas BT; Stringer K; Huang D; Schnaidt J; Goddard-Eckrich D; El-Bassel N; Gilbert L
    Int J Drug Policy; 2021 Nov; 97():103321. PubMed ID: 34358803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia.
    Nielsen S; Olsen A
    Int J Drug Policy; 2021 Apr; 90():103061. PubMed ID: 33321285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
    Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
    Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of a Multicomponent Educational Intervention on Community Pharmacy-Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial.
    Hohmann LA; Fox BI; Garza KB; Wang CH; Correia C; Curran GM; Westrick SC
    Ann Pharmacother; 2023 Jun; 57(6):677-695. PubMed ID: 36047381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
    Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
    Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
    Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR
    J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
    Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
    Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
    J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naloxone Availability in Retail Pharmacies and Neighborhood Inequities in Access.
    Egan KL; Foster SE; Knudsen AN; Lee JGL
    Am J Prev Med; 2020 May; 58(5):699-702. PubMed ID: 32005590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
    Picco L; Lam T; Xia T; Nielsen S
    Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.